AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT06425900
Drug: Winlevi (Clascoterone) cream 1%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dosed twice daily (BID)
Trial: NCT06087406
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% sodium chloride administered intravenously
Trial: NCT04789070
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05935085
Drug: ANB032
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BTLA agonist antibody
Trial: NCT05935085
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06486051
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 500 mg/m\^2/day IV for three consecutive days
Trial: NCT04728711
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo, 600 mg administered orally twice daily (PO bid) for minimum 1 week
Trial: NCT05606341
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sterile saline injection supplied by the NYU Investigational Pharmacy.
Trial: NCT06506422
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10mg Placebo daily for 12 weeks
Trial: NCT05636618
Drug: [212Pb]VMT-α-NET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered every 8 weeks for a maximum of four doses
Trial: NCT05636618
Drug: [212Pb]VMT-α-NET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with positive uptake on FDA approved SSTR2 PET/CT will receive a fixed dose of \[212Pb\]VMT-α-NET IV administered at the RPh2D and schedule determined in Phase I dose escalation
Trial: NCT05588843
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral capsule
Trial: NCT05305547
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered as a round tablet.
Trial: NCT06136650
Drug: Hydrocortisone
RxNorm normalized name: Hydrocortisone
DrugBank: Hydrocortisone succinate (DB14545)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Administered orally or IM as a rescue drug
Trial: NCT05411484
Drug: NanoDOX® Hydrogel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NanoDOX® Hydrogel (Doxycycline Monohydrate USP) will be applied on the areas of the skin previously treated by the Co2 Ablative Fractional Laser and also on a small non treated area of the subject's skin
Trial: NCT05071430
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: HB-1 matched placebo
Trial: NCT06474598
Drug: MTX228
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolimidone was developed as a treatment for gastric ulcers but did not advance beyond phase 2 clinical trials because of lack of efficacy. Subsequently, tolimidone has been identified as an activator of Lyn kinase and was considered as a treatment for type 2 diabetes as an insulin sensitizer because of Lyn's interaction with insulin signaling molecules. More recently, Lyn has been identified as a critical regulator of beta-cell mass, with genetic and biochemical inactivation of Lyn provoking beta-cell death in isolated human islets and precipitated diabetes in mice, and activation of Lyn stimulating beta-cell survival and beta-cell proliferation. These findings strongly suggest that small molecule activators of Lyn, such as Tolimidone, could represent new therapeutic options to promote beta-cell regeneration in type 1 diabete
Trial: NCT04721548
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL of solution twice a day.
Trial: NCT05706129
Drug: [68Ga]Ga-DPI-4452
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[68Ga\]Ga-DPI-4452, administered as IV injection.
Trial: NCT05859750
Drug: Liposomal Irinotecan, Oxaliplatin, 5-Fluorouracil/Calcium folinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: liposomal irinotecan 50 mg/m², oxaliplatin 60 mg/m², leucovorin 400 mg/m², and fluorouracil 2400 mg/m², administered sequentially as a continuous intravenous infusion over 46 h
Trial: NCT05859750
Drug: Oxaliplatin + Irinotecan + 5-Fluorouracil/Leucovorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oxaliplatin, 85 mg/m²; irinotecan, 180 mg/m²; leucovorin, 400 mg/m²; and fluorouracil, 400 mg/m² given as a bolus followed by 2400 mg per square meter given as a 46-hour continuous infusion, every 2 weeks
Trial: NCT05501288
Drug: Huashi Baidu granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients were given HSBDG the day after randomization, with a dose of 2.5g for age 3 to 6 years, 5 g for age 7 to 12 years, and 10 g for age 13 to 18 years, twice daily for 5 consecutive days.
Trial: NCT06371534
Drug: QL2109
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection 3-5 min D1 (Day 1, single dose)
Trial: NCT06371534
Drug: DARZALEX FASPRO®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: subcutaneous injection 3-5 min D1 (Day 1, single dose)
Trial: NCT05179499
Drug: Norepinephrine
RxNorm normalized name: Norepinephrine
DrugBank: Norepinephrine (DB00368)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Norepinepherine should be prepared and delivered at a concentration of 16 micrograms/ml
Trial: NCT05042973
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo matches the active drug in appearance, odor and labelling.
Trial: NCT06299462
Drug: ATG 5.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG 2.5 mg/kg on days -3 and -2
Trial: NCT06299462
Drug: Cyclophosphamide injection
RxNorm normalized name: cyclophosphamide Injection
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide 50 mg/kg on days +3 and +4
Trial: NCT06299462
Drug: ATG 4.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ATG 2.5 mg/kg on day -2 + 1.5 mg/kg on day -3
Trial: NCT05747534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo will be administered orally four times a day (QID) to participants in the placebo arm.
Trial: NCT05241873
Drug: BLU-451
RxNorm normalized name: Blu-Kote
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BLU-451 will be administered orally by tablet QD or BID on a 21-day treatment cycle
Trial: NCT06197217
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subjects in the Placebo group will receive WPV01 Placebo orally (3 tablets per dose), 3 times daily (TID) for 15 consecutive treatments
Trial: NCT05088421
Drug: BWC0977
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD Cohorts: Double-blind dosing will occur. Six participants will receive single doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort.~MAD Cohorts: Double blind dosing will occur. Six participants in each cohort will receive multiple doses of BWC0977. The dose escalation steps may be altered following review of the safety data upon completion of each cohort. Dosing will commence on the morning of Day 1. Dosing frequency to be confirmed based on safety, tolerability and PK data from SAD cohorts. Daily dosing will continue for a total of 10 consecutive days.
Trial: NCT05088421
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SAD Cohorts: Two participants in each cohort will receive matching placebo. MAD Cohorts: Two participants in each cohort will receive matching placebo.
Trial: NCT05681260
Drug: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard risk Arm A: Induction I followed by Consolidation, extracompartmental Capizzi MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
Trial: NCT05681260
Drug: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard risk Arm B: Induction I followed by Consolidation, extracompartmental high dose MTX, delayed intensification and 96 weeks' maintenance therapy. Twenty-one or twenty-six triple intrathecal injections for CNS negative or positive patients, respectively.
Trial: NCT05681260
Drug: Prednisone,Vincristine, Pegylated-asparaginase, Bortezomib,Cytarabine, Cyclophosphamide, Daunorubicin, 6-mercaptopurine, methotrexate, Dexamethasone, Doxorubicin, Vindesine, Etoposide, Ifosfamide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High Risk T-LBL: Induction I followed by 2 cycles of BFM HR Blocks, delayed intensification and 96 weeks' maintenance therapy. Twenty-four or twenty-eight triple intrathecal injections for CNS negative or positive patients, respectively.
Trial: NCT06147921
Drug: Verasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by sinonasal irrigation.
Trial: NCT04172532
Drug: Peposertib
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT06544291
Drug: Placebo 0mg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 placebo (0 mg) softgel capsules will be administered to participants on one of the three test session days.
Trial: NCT06202079
Drug: GZR4 Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: GZR4 injection s.c., once-weekly, treat-to-target dose
Trial: NCT05723107
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will receive continuation of second or initiate third-line chemotherapy regimen at the discretion and decision of treating oncologist.
Trial: NCT06532136
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Matching placebo orally once daily.
Trial: NCT05036291
Drug: NB004 tablets
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Part1: Dose escalation phase of study drug NB004 monotherapy:~Drug: NB004 tablets~NB004 tablets will be administered orally once daily for repeated 28-day cycles until discontinuation criteria are met.~Part 2: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once a daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA~Part 3: Dose Escalation Phase/ COMBO Dose Expansion Phase for the NB004 in combination with Sotorasib:~Drug: NB004 tablets \& Sotorasib~NB004 tablets will be administered orally once daily for repeated 21-day cycles until discontinuation criteria are met.~Sotorasib will be administered with the recommended dosage per prescribing information approved by the FDA .
Trial: NCT05534984
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Placebo Oral capsules~* Participants weighing 25 kg to less than 40 kg - Placebo for Tecovirimat 400 mg every 12 hours for 14 days~* Participants weighing 40 kg to less than 120 kg - Placebo for Tecovirimat 600 mg every 12 hours for 14 days~* Participants weighing 120 kg and over - Placebo for Tecovirimat 600 mg every 8 hours for 14 days
Trial: NCT05776953
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: IV Ketorolac for pain
Trial: NCT05131022
Drug: NX-5948
RxNorm normalized name: Replesta NX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral NX-5948
Trial: NCT06444815
Drug: VET3-TGI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oncolytic vaccinia virus engineered with immunomodulatory transgenes
Trial: NCT04091295
Drug: DNG64
RxNorm normalized name: I do not have enough information to determine the full generic name for the drug abbreviation 'DNG64'. Drug abbreviations can vary and may not have a standardized full generic name. Without more context about the specific drug or clinical trial data, I cannot provide the full generic name. I apologize that I cannot give you a more definitive answer.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous infusions of DNG64 for treatment of advanced pancreatic cancer, sarcoma and carcinoma of breast
Trial: NCT04148742
Drug: DZD9008
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily dose of DZD9008, except for cycle 0 of Part A, in which a single dose of DZD9008 is administrated. Starting dose of DZD9008 is 50 mg once daily. If tolerated, subsequent cohorts will test increasing doses of DZD9008.
Trial: NCT05463263
Drug: STP938
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Small molecule
Trial: NCT05374785
Drug: CPL409116
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPL409116 contained in the tablet called PG242 (60 mg)
Trial: NCT05643534
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will be randomized to receive matching placebo
Trial: NCT06440967
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT06440967
Drug: Aromatase inhibitor
RxNorm normalized name: Aromatase inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral
Trial: NCT02632994
Drug: LY2503029
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT02632994
Drug: LY3023414
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered orally.
Trial: NCT05328752
Drug: XXB750
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XXB750
Trial: NCT05328752
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT05108558
Drug: Control - Crossover to CCH
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be randomized 1:3 into the control arm. After undergoing baseline assessments, control men will not undergo treatments for 6 months. They will then have repeat assessments and receive up to 8 CCH injections. They will then have final assessments performed 6 weeks after treatment.
Trial: NCT04956640
Drug: LY3537982
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral
Trial: NCT06006117
Drug: - Rituximab + Lenalidomide (28-days cycles
FDA approved: no
EMA approved: no
PMDA approved: no
Description: * Lenalidomide PO 20 mg/day, D1-21 from cycle 1 to cycle 6~* Rituximab\* 375 mg/m2 intravenously at Day 1 cycle 1, and then subcutaneous (1400 mg, flat dose) at D1 of cycles 2-12
Trial: NCT06448624
Drug: Placebo 3 days
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for 3 days after CIED implantation
Trial: NCT04986930
Drug: mFOLFIRINOX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: mFOLFIRINOX, every 2 weeks Oxaliplatin, 85 mg/m2, intravenous, day 1 Leucovorin, 400 mg/m2, intravenous, day 1 Irinotecan, 150 mg/m2, intravenous, day 1 fluorouracil, 2,400 mg/m2, intravenous, day 1-2
Trial: NCT05649137
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Participants will receive once-weekly s.c. injection of placebo matched to semaglutide for 72 weeks. Injections may be administered in the thigh, abdomen, or upper arm, at any time of day irrespective of meals.
Trial: NCT06351592
Drug: Placebo (PB)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered by IT injection
Trial: NCT05278104
Drug: Zentiva®
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Zentiva®
Trial: NCT05278104
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT06243575
Drug: Multimodal Intraosseous Femoral Injection
RxNorm normalized name: Sus scrofa temporal lobe preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in femoral canal
Trial: NCT06243575
Drug: Multimodal Intraosseous Tibial Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intraosseous injection of Ketorolac 15mg and Tranexamic acid 500mg in tibial canal
Trial: NCT06360133
Drug: VVN001 Ophthalmic Solution, 5%
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VVN001 Ophthalmic Solution, 5%
Trial: NCT06360133
Drug: VVN001 Ophthalmic Solution, Vehicle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VVN001 Ophthalmic Solution, Vehicle
Trial: NCT06292689
Drug: Cardunolizumab
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1. Not systematically treated:~   Cardunolizumab (10mg/kg) + Cisplatinum (50mg/m2)/ Carboplatinum (AUC 4-5) + Paclitaxel (175mg/m2) ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment.~2. Previous systematic treatment:~Cardunolizumab (10mg/kg) + Chemotherapy regimen selected by the investigator ± Bevacizumab (15mg/kg) for 6 cycles, every 3 weeks (Q3W), and then Cardunolizumab ± Bevacizumab Q3W maintenance treatment.
Trial: NCT01894308
Drug: Testosterone
RxNorm normalized name: Testosterone
DrugBank: (1,2,6,7-3H)Testosterone (DB14093)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 10,30,50 and 70 mg doses of micronized Testosterone delivered by means of a new liquid transdermal delivery solution, HypoSpray(R)once daily for 7 days or until halted due to systemic or dermal reactions.
Trial: NCT04826822
Drug: Spironolactone + Dexamethasone
RxNorm normalized name: Spironolactone
DrugBank: Spironolactone (DB00421)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Low doses of orally administered spironolactone and dexamethasone
Trial: NCT04826822
Drug: Standard-of-care SARS-CoV-2 treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard-of-care SARS-CoV-2 treatment administered according to the local guidelines
Trial: NCT05521386
Drug: Caffeine
RxNorm normalized name: Caffeine
DrugBank: Caffeine (DB00201)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Single pill in an acute dose of 5 mg per kg of body mass
Trial: NCT05521386
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single pill in an acute dose of 5 mg per kg of body mass
Trial: NCT05335928
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Drug: Standard of care Local standard of care per written policies or guidelines Other Name: SoC
Trial: NCT06433713
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% normal saline infusion
Trial: NCT06515678
Drug: arm A - angiotensin converting enzyme inhibitors (ACEi)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with ACEi monotherapy before or within 6 months following debulking surgery.~ACEi will be defined as any drugs from the Anatomical Therapeutic Classification C09AA with an indication for hypertension, including but not limited to: captopril, enalapril, lisinopril, perindopril, ramipril, quinapril
Trial: NCT06515678
Drug: arm B - calcium channel blockers (CCBs)
RxNorm normalized name: Channel catfish
DrugBank: Channel catfish (DB15548)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with CCB monotherapy before or within 6 months following debulking surgery.~CCBs will be defined as any drugs from the Anatomical Therapeutic Classification C08CA with an indication for hypertension, including but not limited to: amlodipine, felodipine, isradipine, nicardipine, nifedipine
Trial: NCT05403476
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is administered as single daily subcutaneous injection dialed to the same value (dose) as FE 999049 for 6 months.
Trial: NCT05587699
Drug: CKD-843-R
RxNorm normalized name: R
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.5mg/day, 9 Month
Trial: NCT05585346
Drug: Oral vitamin B1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral vitamin B1 10mg, times/day
Trial: NCT05361733
Drug: XFB-19
FDA approved: no
EMA approved: no
PMDA approved: no
Description: XFB-19 is a first-in-class synthetic tetra-peptide (Acetyl-Lys-D-Ala-D-Val-Asp-NH2) that inhibits the activation of the human CCAAT-enhancer binding protein beta (C/EBPβ) thus mediating the activation of lung myofibroblasts. Activation of myofibroblasts is responsible for the development of lung fibrosis in idiopathic pulmonary fibrosis (IPF).
Trial: NCT05361733
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No active ingredient drug use to blind participants and investigators
Trial: NCT04551066
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo will be administered QD orally
Trial: NCT05900895
Drug: 17b-estradiol
RxNorm normalized name: Estradiol
DrugBank: Estradiol acetate (DB13952)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 17b-estradiol will be taken orally three times per day.
Trial: NCT06371664
Drug: Conventional Tray (1 mm)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of conventional individualized bleaching trays (trimmed 1 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
Trial: NCT06371664
Drug: Extended Tray (3 mm)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: General examination with bite-wings. Dental prophylaxis (dental scaling and polishing with an abrasive paste). Alginate impressions of both arches. Creation of extended individualized bleaching trays (trimmed 3 mm above the gingival margin) and a position-finder tray of both arches. Application of the bleaching gel in the bleaching trays during 6-8 hours
Trial: NCT06379867
Drug: HSK3486
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.4 mg/kg, IV bolus administration
Trial: NCT06379867
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: IV bolus administration
Trial: NCT04417114
Drug: Rosuvastatin
RxNorm normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Statin
Trial: NCT06299579
Drug: GD-11 for injection test group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The first dose of GD-11 was administered as soon as possible after randomization and then every 12±1 hour. A total of 20 doses were required.